Market Cap: $47.71M
NI
NurExone Biologic Inc.
NRX.V
TSXV (Toronto Stock Exchange Ventures)CAD
Market Cap: $47.71M
The quarter, in plain language Reporting quarters at preclinical-stage biotechs matter less for the current-period P&L and more for what the operational activity around them signals about the pace of…
TORONTO and HAIFA, Israel, Aug. 31, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“ NurExone ” or the “ Company ”), a biotechnology company developing exosome-…
Most preclinical biotech companies are single-indication, cash-burning bets. One drug, one indication, one binary FDA outcome years in the future, and steady dilution in the meantime. NurExone Biologi…
- On August 12, 2026, NurExone Biologic Inc. (TSXV: NRX, OTCQB: NRXBF, FSE: J90) announced that its U.S. subsidiary Exo-Top Inc. had signed a binding memorandum of understanding with Made Scientific,…
Roughly 900,000 people around the world sustain a new acute spinal cord injury every year. About 18,000 of them are in the United States. The lifetime direct-care cost for a single patient often excee…
Nanotechnology is transforming industry and medicine – and NurExone Biologic Inc. is positioning itself at the heart of this future market with its exosome-based platform. With progress in reproducibl…